BULLFROG AI HOLDINGS, INC. Research and Development Expense
BULLFROG AI HOLDINGS, INC. (BFRG) reported Research and Development Expense of $339.46 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- BULLFROG AI HOLDINGS, INC. research and development expense for the quarter ending 2026-06-30 was $339.46K, a 29.32% decline year-over-year.
- BULLFROG AI HOLDINGS, INC. research and development expense for the quarter ending 2026-03-31 was $434.82K, a 24.54% decline year-over-year.
- BULLFROG AI HOLDINGS, INC. research and development expense for the quarter ending 2025-12-31 was $397.19K, a 32.78% decline year-over-year.
- BULLFROG AI HOLDINGS, INC. research and development expense for the quarter ending 2025-09-30 was $345.99K, a 38.93% decline year-over-year.
- BULLFROG AI HOLDINGS, INC. research and development expense for fiscal 2025 was $1.80M, a 19.05% decline from fiscal 2024.
- BULLFROG AI HOLDINGS, INC. research and development expense for fiscal 2024 was $2.22M, a 55.19% increase from fiscal 2023.
- BULLFROG AI HOLDINGS, INC. research and development expense for fiscal 2023 was $1.43M, a 135.14% increase from fiscal 2022.
- BULLFROG AI HOLDINGS, INC. research and development expense for fiscal 2022 was $609.27K, a 2337.08% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $339.46K 10-Q · filed 2026-08-14 | $774.27K 10-Q · filed 2026-08-14 | $1.17M derived: sum of 3 quarters · filed 2026-08-14 | $1.52M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $434.82K 10-Q · filed 2026-05-14 | $832.01K derived: sum of 2 quarters · filed 2026-05-14 | $1.18M derived: sum of 3 quarters · filed 2026-05-14 | $1.66M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $397.19K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $743.18K derived: sum of 2 quarters · filed 2026-03-19 | $1.22M derived: sum of 3 quarters · filed 2026-08-14 | $1.80M 10-K · filed 2026-03-19 |
| 2025-09-30 | $345.99K 10-Q · filed 2025-11-14 | $826.29K derived: sum of 2 quarters · filed 2026-08-14 | $1.40M 10-Q · filed 2025-11-14 | $1.99M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $480.30K 10-Q · filed 2026-08-14 | $1.06M 10-Q · filed 2026-08-14 | $1.65M derived: sum of 3 quarters · filed 2026-08-14 | $2.21M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $576.26K 10-Q · filed 2026-05-14 | $1.17M derived: sum of 2 quarters · filed 2026-05-14 | $1.73M derived: sum of 3 quarters · filed 2026-05-14 | $2.25M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $590.86K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.16M derived: sum of 2 quarters · filed 2026-03-19 | $1.67M derived: sum of 3 quarters · filed 2026-03-19 | $2.22M 10-K · filed 2026-03-19 |
| 2024-09-30 | $566.58K 10-Q · filed 2025-11-14 | $1.08M derived: sum of 2 quarters · filed 2025-11-14 | $1.63M 10-Q · filed 2025-11-14 | $2.04M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $513.70K 10-Q · filed 2025-08-13 | $1.07M 10-Q · filed 2025-08-13 | $1.47M derived: sum of 3 quarters · filed 2025-08-13 | $1.85M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $552.13K 10-Q · filed 2025-05-13 | $961.12K derived: sum of 2 quarters · filed 2025-05-13 | $1.34M derived: sum of 3 quarters · filed 2025-05-13 | $1.61M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $409.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $789.01K derived: sum of 2 quarters · filed 2025-03-14 | $1.06M derived: sum of 3 quarters · filed 2025-03-14 | $1.43M 10-K · filed 2025-03-14 |
| 2023-09-30 | $380.01K 10-Q · filed 2024-11-08 | $653.69K derived: sum of 2 quarters · filed 2024-11-08 | $1.02M 10-Q · filed 2024-11-08 | $1.18M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $273.67K 10-Q · filed 2024-08-07 | $643.60K 10-Q · filed 2024-08-07 | $804.50K derived: sum of 3 quarters · filed 2024-08-07 | $843.92K derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $369.93K 10-Q · filed 2024-05-10 | $530.83K derived: sum of 2 quarters · filed 2024-05-10 | $570.25K derived: sum of 3 quarters · filed 2024-05-10 | $662.92K derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $160.90K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $200.32K derived: sum of 2 quarters · filed 2024-03-29 | $292.99K derived: sum of 3 quarters · filed 2024-03-29 | $609.27K 10-K · filed 2024-03-29 |
| 2022-09-30 | $39.42K 10-Q · filed 2023-11-14 | $132.09K derived: sum of 2 quarters · filed 2023-11-14 | $448.38K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $92.67K 10-Q · filed 2023-08-14 | $408.95K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $316.28K 10-Q · filed 2023-05-24 | |||
| 2021-12-31 | $25.00K 10-K · filed 2023-04-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B |